Copyright © Inderes 2011 - present. All rights reserved.
Log in
Search
Latest
Markets
Morning Review
Stock Comparison
Financial Calendar
Dividends Calendar
Research
Articles
Insider Transactions
Transcripts
AGM Invitations
inderesTV
Portfolio
Forum
Premium
Femme
Nora AI
Learn
Investing School
Q&A
Analysis School
About Us
Our Coverage
Team
Collapse
Language
Log in to your Inderes Free account to see all free content on this page.
Create account
Sign in
Happy Helper
Follow
Less than
1K
followers
Forum discussions
Johnson & Johnson had a good third quarter; revenue and earnings exceeded expectations, and the company also raised its outlook for this year. Both the pharmaceutical side and medical devices grew strongly, and earnings also clearly improved from last year. The company plans to spin...
Johnson & Johnson says it has reached an agreement with the Trump administration to lower drug prices for Americans. In exchange, the company will receive an exemption from U.S. tariffs on pharmaceuticals. J&J plans to participate in the TrumpRx.gov program and promise “more comparable...
The company’s “final quarter” beat expectations in terms of both earnings and revenue. The overall performance looked quite okay, nothing too surprising – at the time of writing, it’s down 3.5% in the pre-market, but let’s see what happens when the market opens. Growth was driven...
Johnson & Johnson now faces over 73,000 lawsuits, as its talcum powder is alleged to cause cancer. The company’s settlement attempt was rejected, the product was removed from the market, but J&J nevertheless denies the allegations and caps potential compensation at $9 billion. Johnson...
A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died of mesothelioma, as the court found that the company’s talc products contained asbestos and caused cancer. J&J denies the allegations and plans to appeal; additionally, the company ...
According to the article below, Johnson & Johnson is planning to sell its DePuy Synthes unit, which specializes in orthopedic surgery. The value of the deal is expected to exceed $20 billion. According to the article, private equity firms and industry competitors have shown interest...
Johnson & Johnson acquired Halda Therapeutics for $3.05 billion and gained a cancer drug platform as well as a prostate cancer drug candidate. Returns may come later (or maybe not :D), but in the coming years, the deal will weigh on earnings according to the article. The acquisition...
Read more on our forum
Inderes’ Disclaimer can be found
here
. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.